Opendata, web and dolomites

MEISi SIGNED

Druggable Small Molecule Inhibitor of MEIS Proteins

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MEISi project word cloud

Explore the words cloud of the MEISi project. It provides you a very rough idea of what is the project "MEISi" about.

ending    class    tools    discovery    protein    small    risk    feasibility    national    modulate    nearly    segment    efforts    meinox    metabolism    tackling    customers    noncommunicable    2018    10m    cardiovascular    proper    71    never    sizes    massive    ingredients    substance    molecular    innovative    pct    deadliest    cvds    cancer    diabetes    validated    deep    regulations    indicate    published    molecule    conduct    active    owing    oncology    patented    benchmarking    stem    prestigious    channels    first    29    accounting    hoxa9    commercialization    market    significance    countries    nature    meisi    global    co    drug    meis    share    tech    selective    markets    pending    deaths    biology    inhibits    usd    druggable    globally    diseases    3b    critical    mechanisms    44    startup    performing    pharmaceutically    family    company    cell    entry    journals    benefit    therapeutics    inhibitors    strategies    pbx    motivates    plays    plan    proteins    strategy    tgif2    ncds    competitive   

Project "MEISi" data sheet

The following table provides information about the project.

Coordinator
MEINOX ILAC TEKNOLOJILERI AS 

Organization address
address: RESITPASA MAH. KATAR CAD. TEKNOKENT ARI 1 NO: 2/5 ICKAPI NO: 19
city: SARIYER ISTANBUL
postcode: 34467
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Turkey [TR]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-12-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    MEINOX ILAC TEKNOLOJILERI AS TR (SARIYER ISTANBUL) coordinator 50˙000.00

Map

 Project objective

MEISi is the first innovative product of Meinox as a druggable substance, owing to its years of research on MEIS biology (published in prestigious journals like Nature and Cell Stem Cell, and PCT patented - pending national entry in 44 countries). Meinox targets the deadliest noncommunicable diseases (NCDs); cancer, CVDs and diabetes, together accounting for nearly 71% of all deaths globally. Never ending efforts and global targets in tackling these diseases show the importance of the development of more effective therapeutics.

MEISi is a druggable target-based small molecule, developed and validated by Meinox. MEISi inhibits the activity of MEIS protein which plays a critical role in cell metabolism and associated with NCDs. The benefit it presents to the targeted drug discovery market is to provide tools to modulate molecular mechanisms of the NCDs. The massive sizes of oncology and cardiovascular drug markets (USD $ 29.3B globally) indicate the significance of the small molecule drug discovery market which motivates Meinox to target €10M market share in 3 years after commercialization.

Meinox is a deep-tech startup established in 2018 with the main focus on novel and high-level pharmaceutically active ingredients. The company aims to research, develop, produce and market first-in-class, selective drug-like small molecule inhibitors of MEIS, PBX and TGIF2 proteins and their co-factor HOXA9.

Meinox aims to conduct a feasibility study with a risk analysis based on different market regulations. In order to improve the commercialization plan, potential customers of MEISi will be identified and strategies will be developed for each segment by defining proper channels for the MEISi product family. Market entry strategy will be validated by performing market analysis and competitive benchmarking in the target markets.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MEISI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MEISI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More